JPRN-UMIN000014632已完成2 期
The phase II study of induction chemotherapy with cetuximab/S-1/low dose cisplatin for oral squamous cell carcinoma patients - Induction chemotherapy with cetuximab/S-1/low dose cisplatin for oral squamous cell carcinoma patients
The workshop of chemotherapy for oral cancer0 个研究点目标入组 55 人开始时间: 2014年7月25日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 55
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)double cancer case 2)severe systemic complications 3)metastasis to CNS 4)ischemic heart disease 5)active gastrointestinal ulcer 6)severe mental disorder 7) women who are fertile or during pregnancy 8) past illness of severe drug allergy 9) attending doctor's decision as unsuitable patient for this study
研究者
相似试验
招募中
不适用
A phase 2 study of induction chemotherapy followed by chemoradiotherapy for patients with borderline resectable pancreatic cancerPancreatic cancerJPRN-UMIN000034410Keio University School of Medicine40
进行中（未招募）
1 期
Phase I/II study of Induction Chemotherapy with weekly RAD001, Carboplatine and Paclitaxel in Unresectable or Inoperable Locally Advanced Head and NeckSquamous Cell Carcinoma (HNSCC) - CAPRAnresectable or Inoperable locally advanced head and neck squamous cellcarcinoma without any prior chemotherapy or radiotherapyMedDRA version: 9.1Level: PTClassification code 10041823Term: Squamous cell carcinomaEUCTR2008-005702-39-FRGERCOR50
已完成
1 期
Phase I/II study of induction chemotherapy with docetaxel,cisplatin and fluorouracil (DCF) followed by chemoradiotherapy in patients with unresectable locally advanced esophageal carcinoma.esophageal neoplasmJPRN-UMIN000003370ational Cancer Center Hospital East30
未知
2 期
A Phase II study of induction chemotherapy S-1 and CDDP in patients with FDG-PET positive N2 disease of non-small cell lung cancer.JPRN-C000000358Fukushima Medical University25
进行中（未招募）
不适用
Phase I/II study on induction chemotherapy followed by chemoradiation with or without lapatinib, a dual EGFR/ErbB2 kinase inhibitor, in patients with locally advanced resectable larynx and hypopharynx squamous cell carcinomaEUCTR2006-002667-33-BEEuropean Organisation for Research and Treatment of Cancer